In this study, we present the clinicopathologic features and immunophenotypic characteristics of five cases of uterine tumors resembling ovarian sex cord tumors and three cases of endometrial stromal tumors with sex cord-like elements, with emphasis on immunohistochemical markers of sex cord differentiation. The mean patient age was 42 years (range 19-69 years), and vaginal bleeding was the most common clinical presentation. The tumors were usually polypoid masses arising in the uterine fundus, with a mean tumor size of 6.7 cm. Sex cord patterns in uterine tumors resembling ovarian sex cord tumors, including anastomosing cords, trabeculae, small nests, tubules, and in one case, a striking retiform architecture with Leydig-like cells, comprised from 70 to 100% of the tumor volume. All uterine tumors resembling ovarian sex cord tumors were positive for two or more markers of sex cord differentiation; all five cases showed strong immunoreactivity for calretinin, with coexpression of CD99 (four cases), Melan-A (two cases), and inhibin (two cases). Endometrial stromal tumors with sex cord-like elements were less frequently positive for markers of sex cord differentiation, with each case positive for one marker (calretinin, two cases; CD99, one case). In addition, all eight cases were frequently positive for cytokeratin, CD10, vimentin, estrogen receptor, and progesterone receptor; desmin immunoreactivity, when present, was limited to minor foci of smooth muscle. Overall, the morphologic and immunohistochemical findings in uterine tumors resembling ovarian sex cord tumors strongly support that these unusual uterine tumors are polyphenotypic neoplasms with true sex cord differentiation.
Uterine tumors resembling ovarian sex cord tumors (UTROSCT) are an unusual group of stromal neoplasms exhibiting prominent sex cord-like differentiation. In their initial description almost 30 years ago, UTROSCT were designated as Group II tumors, characterized by benign behavior, to distinguish them from endometrial stromal tumors with sex cord-like elements (ESTSCLE; Group I tumors) which were associated with increased risk of recurrence and metastasis. 1 UTROSCT are placed in the miscellaneous category in the most recent World Health Organization classification of tumors of the uterine corpus, 2 although most investigators consider these rare neoplasms to be variants of endometrial stromal tumors. 3 UTROSCT show a predominant, if not exclusive, pattern of cords, nests, and trabeculae resembling granulosa or Sertoli cell tumors of the ovary, while ESTSCLE contain focal sex cord-like areas in a background of an otherwise typical endometrial stromal nodule or endometrial stromal sarcoma. True Leydig cell differentiation has not been described in these tumors, although some cases have been observed to contain luteinized-like cells with abundant eosinophilic or foamy cytoplasm. [4] [5] [6] [7] Numerous immunohistochemical and ultrastructural studies have attempted to phenotype the sex cord-like cells in UTROSCT and ESTSCLE, with variable evidence supporting myoid, [8] [9] [10] [11] [12] [13] [14] epithelial, 4, 15 and true sex cord differentiation. 6, 7, [16] [17] [18] [19] [20] Specifically, inhibin and CD99, 3, 6, 7, 14, [17] [18] [19] [20] [21] as well as Melan-A, 19, 21 and most recently, calretinin, 7, 20 have been utilized as immunohistochemical markers of sex cord differentiation in UTROSCT and ESTSCLE based on application of these markers to sex cordstromal tumors of the ovary. [22] [23] [24] [25] [26] [27] [28] [29] The present study was initiated following the diagnosis of a UTROSCT exhibiting a striking retiform pattern and Leydig-like stromal cells, indistinguishable from a Sertoli-Leydig cell tumor of the ovary. This index case prompted an immunohistochemical and clinicopathologic study of UTROSCT and ESTSCLE, with emphasis on the more recently used markers of sex cord differentiation. We sought to determine the diagnostic utility of these and other markers and to contribute to the understanding of the phenotype and behavior of these unusual tumors.
Materials and methods
Five UTROSCT and three ESTSCLE were retrieved from the consultation files of one of the authors (JP). Clinical information, including presenting symptom, surgery, adjuvant therapy, and patient outcome was obtained from the contributing pathologists and gynecologists. All available pathology reports were examined and the diagnosis confirmed in each case by review of hematoxylin-and eosin-stained slides. Tumors were evaluated for approximate proportions of sex cord, endometrial stromal, and smooth muscle elements; tumors with predominant (450%) or minor (r50%) sex cord differentiation were diagnosed as UTROSCT and ESTSCLE, respectively. Other histologic parameters including infiltrative margins, vascular invasion, nuclear atypia, mitotic index, and necrosis were also assessed.
Immunohistochemistry was performed on all eight cases for calretinin, melan A, CD99, inhibin, CD10, desmin, cytokeratin (CAM 5.2), vimentin, estrogen receptor, and progesterone receptor. Sources and dilutions of these antibodies are provided in Table 1 . Heat-induced antigen retrieval was conducted by immersion of the sections in sodium citrate buffer (0.01 M sodium-citrate monohydrate, pH 6.0) or EDTA buffer (pH 8.0) and incubation in an autoclave (Matachana, Barcelona, Spain) at 1201C for 10 min. The immunohistochemical reactions were performed in a Dako TechMate Horizon immunostainer and visualized following the EnVision system with diaminobenzidine as the chromogen. Immunohistochemical staining was graded as 0 (negative), 1 þ (o10% positive cells), 2 þ (10-50% positive cells), or 3 þ (450% positive cells). Positive tissue control and negative control slides, the latter performed by omission of the primary antibody, were included with each batch of immunohistochemical slides.
Results
The clinicopathologic features for all eight cases are presented in Tables 2 and 3 . The mean patient age was 42 years (range 19-69 years); the most common clinical presentation was vaginal bleeding (data not shown). Patients underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy (four cases) or simple hysterectomy (four cases). Evidence of extrauterine spread was present in one patient with ESTSCLE.
Most tumors were polypoid or nodular masses, usually located in the uterine fundus, with a mean tumor size of 6.7 cm (range 3.5-14 cm). Infiltrative margins were noted in two UTROSCT and in two ESTSCLE. Microscopically, two UTROSCT consisted exclusively of sex cord elements; one of these, the index case (case 1), exhibited a striking retiform pattern, with many small papillae showing hyalinized cores lined by cuboidal cells (Figure 1a ). Discrete nodules of polygonal, Leydig-like cells with abundant eosinophilic cytoplasm and round nuclei were scattered throughout the tumor (Figure 1b) . Crystals of Reinke were not identified. In the remaining cases, sex cord patterns in both UTROSCT and ESTSCLE were variable but most commonly consisted of thin anastomosing cords, trabeculae, small nests, and tubules (Figure 2a and b). Cells typically had scant cytoplasm and round to oval nuclei with indistinct nucleoli. Nuclear atypia was mild to moderate in all eight cases. The mitotic index was low in the UTROSCT group, ranging from one to three mitoses per 10 high-power fields, and up to six mitoses per 10 high-power fields in the ESTSCLE group. Necrosis was present only in the largest tumor of the series (case 7). Vascular invasion was present in all three ESTSCLE but in only one UTROSCT. Of the three ESTSCLE, two tumors demonstrated usual low-grade endometrial stromal sarcoma; one case consisted of high-grade stromal sarcoma (case 7).
The immunohistochemical profile of each case and their relative proportions of sex cord, endometrial stromal, and smooth muscle elements are given in Table 4 . Each of the five UTROSCT cases were immunoreactive for two or more markers of sex cord differentiation. All five UTROSCT were strongly immunoreactive for calretinin, with coexpression of CD99 in four cases, melan-A in two cases, and inhibin in two cases. The index UTROSCT case showed immunoreactivity for calretinin ( Figure 1c ) and melan-A (Figure 1d ) in both the Sertoli-and Leydig-like components, while only the latter was positive for inhibin. Three of the remaining UTROSCT cases and all three ESTSCLE were inhibin negative. In case 4, the sex cord cell and foam cell components showed immunoreactivity for calretinin, CD99, and inhibin (Figures 2d-f ). Immunohistochemical staining for calretinin was present in two of three ESTSCLE but with less intensity than that observed in the UTROSCT group. All three ESTSCLE were negative for Melan A; one case was immunoreactive for CD99.
CD10 was variably positive in 4/5 UTROSCT and strongly positive in 2/3 ESTSCLE. Of the five cases Uterine tumors resembling ovarian sex cord tumors JA Irving et al with desmin immunoreactivity, four showed positive staining only in the smooth muscle component. All eight cases were strongly immunoreactive for vimentin, and the majority (6/8 cases) were cytokeratin positive. Three UTROSCT showed ER immunoreactivity, in two cases restricted to the sex cord elements, while four UTROSCT were PR positive. Two ESTSCLE were positive for both ER and PR. Information regarding adjuvant therapy and clinical follow-up was available for seven patients (Table 2) . For four patients with UTROSCT, three received no additional treatment and one underwent pelvic radiotherapy with brachytherapy to the vaginal vault; all four patients were alive without evidence of disease at a mean of 3.5 years. The fourth patient (case 3) had no residual tumor in the hysterectomy specimen and was subsequently lost to follow-up. Of the three patients with ESTSCLE, two received no additional therapy and are without evidence of disease at 1 year 3 months and 2 years. The third patient (case 7) received chemotherapy but developed pulmonary and bony metastases and died of disease 10 months from the operative date.
Discussion
Since the initial description of UTRSOCT in 1976, there have been numerous efforts to further characterize this unusual group of uterine neoplasms. Results have been variable, with ultrastructural and immunohistochemical evidence of myogenic, epithelial, and sex cord differentiation. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] In the present study, we applied a panel of antibodies, inclusive of the most recently identified markers of sex cord differentiation (calretinin, melan A, CD99, and inhibin) as well as smooth muscle and endometrial stroma, to a series of UTROSCT and ESTSCLE. We found that all UTROSCT were immunoreactive for at least two markers of sex cord differentiation, often with coexpression of cytokeratin, CD10, vimentin, estrogen receptor, and progesterone receptor; desmin immunoreactivity, when present, was restricted to minor foci of smooth muscle. Our results support that UTROSCT are polyphenotypic neoplasms with true sex cord differentiation. As shown in Table 5 , our data are in general agreement with previous studies addressing the issue of immunohistochemical expression of sex cord markers in UTROSCT 6, 7, 14, [17] [18] [19] [20] [21] 24, 30 and is the first to concurrently examine the four most commonly used markers. This literature review also highlights that ESTSCLE, or Type I tumors, less frequently show immunoreactivity for markers of sex cord differentiation, a finding which correlates with their morphologic appearance and relatively minor component of sex cord elements. 6, 14, 18 Of the five UTROSCT analyzed in this study, the proportion of sex cord elements comprised between 70 and 100% of the tumor volume, based on routine microscopic evaluation. In most cases, the sex cord formations consisted of thin cords, trabeculae, and nests of cells; in the index case, a striking retiform pattern with interspersed clusters of eosinophilic Leydig-like cells was present, indistinguishable from an ovarian Sertoli-Leydig cell tumor. Eosinophilic cells resembling luteinized stromal cells have been described, 6, 7 as well as foam cells, 1,4,6,7 both of which have shown strong inhibin and CD99 immunoreactivity. 6, 7 In our index UTROSCT case, composed exclusively of sex cord elements, inhibin immunoreactivity was restricted to the Leydig-like cell component, while calretinin and Melan-A were diffusely positive. The morphology and immunophenotype of foam cells, eosinophilic 'luteinized' cells, and Leydig-like cells suggests that they represent a spectrum of variably differentiated sex cord cells. Indeed, some authors have suggested that these cells may have steroid-producing function, although this remains speculative at present. 7 Overall, calretinin was the most consistently expressed sex cord marker, present in 450% of cells in all five UTROSCT and in two of three ESTSCLE (o10 and 10-50% of tumor cells positive). To the best of our knowledge, description of calretinin immunoreactivity in UTROSCT is limited to two previous case reports, both of which have also been positive (Table 2) ; 7, 20 this is the first report of calretinin immunostaining in ESTSCLE. Calretinin, a calcium-binding protein, is expressed by theca interna cells, hilus cells, a minor proportion of individual stromal cells, and surface epithelium of the normal ovary, 27 and has recently emerged as a 27 Studies have shown that calretinin may be a more sensitive marker than inhibin in this setting, and be of particular use in ovarian sex cord-stromal tumors that are inhibin negative. 28 However, calretinin is less specific than inhibin, with one study reporting positivity in approximately one-quarter of ovarian surface epithelial carcinomas tested, compared with only 2% showing inhibin positivity.
28
CD99 is the MIC2 gene product initially heralded as a marker for Ewing's sarcoma and peripheral neuroectodermal tumor, which, similar to calretinin, stains sex cord-stromal tumors of the ovary and testis as well as their normal cell counterparts. 24, [31] [32] [33] Membranous CD99 immunostaining can be positive in other mesenchymal uterine neoplasms including leiomyoma variants and endometrial stromal tumors, lessening its utility as a differential diagnostic marker in this setting. 30 However, it is noteworthy that 24 of 28 UTROSCT (86%) have been CD99-positive (Table 5) . 6, 7, 17, 19, 21, 24, 30 Studies of Melan-A expression in UTROSCT are limited. Two of five UTROSCT in the present study were focally Melan-A positive, similar to Krishnamurthy et al 17 who found four of seven UTROSCT positive for Melan-A in o10 to 10-50% of tumor cells. As Melan-A stains steroid-producing cells in the ovary, testis, and adrenal cortex, 34 it has been suggested that Melan-A immunoreactivity in UTROSCT supports a specialized gonadal stromal phenotype. 17 A component of smooth muscle can be seen in UTROSCT, recognizable on routine staining as small bundles and nodules of cells very similar to normal myometrium. 3 In our experience, these foci are highlighted by desmin immunostaining. Although a diffuse pattern of desmin immunoreactivity in UTROSCT has been reported, 3, 30 this finding warrants strong consideration of a smooth muscle neoplasm, including epithelioid variants; h-caldesmon is usually negative in UTROSCT and positive in uterine smooth muscle tumors, and is a more useful marker in this distinction. 30 It is unclear whether the bundles of smooth muscle in UTROSCT represent entrapped normal tissue or a divergent line of differentiation. 3 Our morphologic and immunohistochemical findings indicate that UTROSCT arise from pluripotent mesenchymal cells, which predominantly differentiate into sex cord cells. Evidence supports that focal smooth muscle and endometrial stromal cell differentiation can also occur. Accordingly, we recommend the use of an immunohistochemical panel to facilitate the diagnosis of UTROSCT, including two markers of sex cord differentiation (calretinin and one of either melan A, CD99, or inhibin), desmin, cytokeratin, and CD10. This panel should discriminate between UTROSCT and smooth muscle neoplasms, as the latter should be negative for sex cord markers, cytokeratin, and usually CD10, but diffusely positive for desmin. Distinction of UTROSCT from endometrial stromal tumors can be subjective, but we agree with that UTROSCT is a designation that should be reserved for tumors with predominant (450%) or exclusive sex cord differentiation.
The long-term clinical behavior of UTROSCT remains to be established. Although favorable histologic features including well-circumscribed borders and an absence of vascular invasion are usually present, these tumors may on occasion show infiltrative borders and focal vascular invasion, albeit not to the extent that is characteristic of endometrial stromal sarcomas. Four of our cases with follow-up, including two cases with either or both infiltrative margins and focal vascular invasion, have had favorable outcomes. However, as the duration of follow-up is still limited, we and others advocate consideration of these neoplasms as having an uncertain but probably low likelihood of recurrence, with acknowledgement that no extrauterine spread or distant metastasis have been reported. 1, 3 
